Type 1 Diabetes Mellitus Clinical Trials in Indianapolis, Indiana

5 studies are recruiting for type 1 diabetes mellitus in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Type 1 Diabetes Extension Study

   This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long…

   Stage

   Not phased

   Ages

   8 to 35

   Site

   Indiana University Riley Hospital for Children, Indianapolis, Indiana

   Locations

   12 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT02734277 on ClinicalTrials.gov

2. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   Riley Hospital for Children- Indiana University, Indianapolis, Indiana

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

3. Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

   This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once eve…

   Stage

   Phase 2

   Ages

   8 to 45

   Site

   Indiana University-Riley Hospital for Children, Indianapolis, Indiana

   Locations

   15 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07142252 on ClinicalTrials.gov

4. INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

   INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to <18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of …

   Stage

   Phase 2

   Ages

   6 to 17

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   10 in total

   Run by

   Mannkind Corporation

   See if you can join NCT07224321 on ClinicalTrials.gov

5. Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

   This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

   Stage

   Not phased

   Ages

   14 to 75

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   11 in total

   Run by

   Insulet Corporation

   See if you can join NCT07579702 on ClinicalTrials.gov